Marshall Wace’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Marshall Wace’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-296,462	Closed	-$22.3M	–	4030
2022 Q2	$22.3M	Buy	+296,462	New	+$13.2M	0.05%	421
2021 Q1	–	Sell	-13,115	Closed	-$1.6M	–	3012
2020 Q4	$1.6M	Buy	13,115 +63	+0.5%	+$6.9K	0.01%	1039
2020 Q3	$1.14M	Hold	13,052	–	–	0.01%	978
2020 Q2	$843K	Buy	13,052 +8,953	+218%	+$516K	0.01%	1048
2020 Q1	$183K	Buy	+4,099	New	+$218K	﹤0.01%	1195

Marshall Wace's TPTX Position: Q3 2022 in Review

Marshall Wace sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 296,462 shares — an estimated $22.3M sold.

Marshall Wace first reported a position in TPTX in Q1 2020 and held it in 5 quarters. The position peaked at $22.3M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Marshall Wace reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Marshall Wace sold 296,462 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $22.3M.
Marshall Wace first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
Marshall Wace's Turning Point Therapeutics, Inc. Common Stock position peaked at $22.3M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Marshall Wace's 13F filing for Q3 2022, filed 14 Nov 2022.